Publications by authors named "Maria Castillo de la Osa"
Article Synopsis
- The study evaluated the immune response to SARS-CoV-2 variants in individuals who had recovered from COVID-19, focusing on two groups based on the time elapsed since infection (1-3 months vs. 4-12 months).
- It found that recovered individuals had higher antibody levels compared to naïve participants after vaccination, especially after receiving their second dose.
- Longer intervals between infection and vaccination (more than 3 months) significantly improved the effectiveness of the immune response against various strains of the virus, highlighting the importance of timing in vaccination strategies.
Article Synopsis
- The CombiVacS study examined the effectiveness and safety of combining two COVID-19 vaccines, ChAdOx1-S and BNT162b2, with initial results showing a robust immune response after 14 days.
- A secondary analysis tracked the immune response in 664 adults from the initial study up to 180 days, measuring both humoral (antibody levels) and cellular (T-cell response) immunity.
- By day 180, antibody levels declined significantly in both the intervention and control groups, indicating waning immunity over time, with notably lower responses to different COVID-19 variants.
Immune response and reactogenicity after immunization with two-doses of an experimental COVID-19 vaccine (CVnCOV) followed by a third-fourth shot with a standard mRNA vaccine (BNT162b2): RescueVacs multicenter cohort study.
EClinicalMedicine
September 2022
Background: There is no evidence to date on immunogenic response among individuals who participated in clinical trials of COVID-19 experimental vaccines redirected to standard national vaccination regimens.
Methods: This multicentre, prospective controlled cohort study included subjects who received a COVID-19 experimental vaccine (CVnCoV)(test group, TG) - and unvaccinated subjects (control group, CG), selected among individuals to be vaccinated according to the Spanish vaccination program. All study subjects received BNT162b2 as a standard national vaccination schedule, except 8 (from CG) who received mRNA-1273 and were excluded from immunogenicity analyses.
SARS-CoV-2 infection causes COVID-19, ranging from mild to critical disease in symptomatic subjects. It is essential to better understand the immunologic responses occurring in patients with the most severe outcomes. In this study, parameters related to the humoral immune response elicited against SARS-CoV-2 were analysed in 61 patients with different presentations of COVID-19 who were recruited in Hospitals and Primary Healthcare Centres in Madrid, Spain, during the first pandemic peak between April and June 2020.
View Article and Find Full Text PDF